TY - JOUR
T1 - The effect of real-time continuous glucose monitoring in pregnant women with diabetes
T2 - A randomized controlled trial
AU - Secher, Anna L
AU - Ringholm, Lene
AU - Damm, Peter
AU - Mathiesen, Elisabeth R
PY - 2013
Y1 - 2013
N2 - OBJECTIVE: To assess whether intermittent real-time continuous glucose monitoring (CGM) improves glycemic control and pregnancy outcome in unselected women with pregestational diabetes. RESEARCHDESIGNANDMETHODSdA total of 123 women with type 1 diabetes and 31 womenwith type 2 diabeteswere randomized to use real-time CGMfor 6 days at 8, 12, 21, 27, and 33 weeks in addition to routine care, including self-monitored plasma glucose seven times daily, or routine care only. To optimize glycemic control, real-time CGMreadings were evaluated by a diabetes caregiver. HbA1c, self-monitored plasma glucose, severe ypoglycemia, and pregnancy outcomes were recorded, with large-for-gestational- age infants as the primary outcome. RESULTS - Women assigned to real-time CGM (n = 79) had baseline HbA1c similar to that of women in the control arm (n = 75) (median 6.6 [range 5.3-10.0] vs. 6.8% [5.3-10.7]; P = 0.67) (49 [34-86] vs. 51 mmol/mol [34-93]). Forty-nine (64%) women used real-time CGM per protocol. At 33 weeks, HbA1c (6.1 [5.1-7.8] vs. 6.1% [4.8-8.2]; P = 0.39) (43 [32-62] vs. 43 mmol/mol [29-66]) and self-monitored plasma glucose (6.2 [4.7-7.9] vs. 6.2mmol/L [4.9-7.9]; P = 0.64) were comparable regardless of real-time CGMuse, and a similar fraction of women had experienced severe hypoglycemia (16 vs. 16%; P = 0.91). The prevalence of large-for-gestational-age infants (45 vs. 34%; P = 0.19) and other perinatal outcomes were omparable between the arms. CONCLUSIONS - In this randomized trial, intermittent use of real-time CGM in pregnancy, in addition to self-monitored plasma glucose seven times daily, did not improve glycemic control or pregnancy outcome in women with pregestational diabetes.
AB - OBJECTIVE: To assess whether intermittent real-time continuous glucose monitoring (CGM) improves glycemic control and pregnancy outcome in unselected women with pregestational diabetes. RESEARCHDESIGNANDMETHODSdA total of 123 women with type 1 diabetes and 31 womenwith type 2 diabeteswere randomized to use real-time CGMfor 6 days at 8, 12, 21, 27, and 33 weeks in addition to routine care, including self-monitored plasma glucose seven times daily, or routine care only. To optimize glycemic control, real-time CGMreadings were evaluated by a diabetes caregiver. HbA1c, self-monitored plasma glucose, severe ypoglycemia, and pregnancy outcomes were recorded, with large-for-gestational- age infants as the primary outcome. RESULTS - Women assigned to real-time CGM (n = 79) had baseline HbA1c similar to that of women in the control arm (n = 75) (median 6.6 [range 5.3-10.0] vs. 6.8% [5.3-10.7]; P = 0.67) (49 [34-86] vs. 51 mmol/mol [34-93]). Forty-nine (64%) women used real-time CGM per protocol. At 33 weeks, HbA1c (6.1 [5.1-7.8] vs. 6.1% [4.8-8.2]; P = 0.39) (43 [32-62] vs. 43 mmol/mol [29-66]) and self-monitored plasma glucose (6.2 [4.7-7.9] vs. 6.2mmol/L [4.9-7.9]; P = 0.64) were comparable regardless of real-time CGMuse, and a similar fraction of women had experienced severe hypoglycemia (16 vs. 16%; P = 0.91). The prevalence of large-for-gestational-age infants (45 vs. 34%; P = 0.19) and other perinatal outcomes were omparable between the arms. CONCLUSIONS - In this randomized trial, intermittent use of real-time CGM in pregnancy, in addition to self-monitored plasma glucose seven times daily, did not improve glycemic control or pregnancy outcome in women with pregestational diabetes.
U2 - 10.2337/dc12-2360
DO - 10.2337/dc12-2360
M3 - Journal article
C2 - 23349548
SN - 0149-5992
VL - 36
SP - 1877
EP - 1883
JO - Diabetes Care
JF - Diabetes Care
IS - 7
ER -